Carolina Ciumas1, Alexandra Montavont, Philippe Ryvlin. 1. CTRS-INSERM IDEE (Institut Des Epilepsies de l'Enfant et de l'adolescent), INSERM U821, CERMEP imagerie du vivant, and Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France.
Abstract
PURPOSE OF REVIEW: The aim of this article is to review the latest clinical trials in neurological diseases where magnetic resonance imaging was used to assess treatment outcome. RECENT FINDINGS: The unique sensitivity of magnetic resonance imaging for detecting disorders in the brain has made it an attractive noninvasive tool for assessing treatment efficacy in several diseases. Volumetric and functional magnetic resonance imaging have proved to represent robust biomarkers for the evaluation of anti-Alzheimer treatments, and have demonstrated a significant impact of cholinesterase inhibitors. The optimization of thrombolytic therapy in acute ischemic stroke has concentrated on the quantification of the ischemic penumbra, using perfusion-weighted and diffusion-weighted imaging. Standard assessment of T2 or fluid-attenuated inversion recovery lesion load remains the method of choice to evaluate new therapeutic strategy in multiple sclerosis. Other nonconventional quantitative magnetic resonance imaging techniques such as magnetic resonance volumetry, magnetization transfer imaging, diffusion-weighted imaging, or magnetic resonance spectroscopy are increasingly used in the field. SUMMARY: Magnetic resonance imaging has become a major surrogate marker of treatment response in clinical trials of neurological disorders, offering the possibility to reduce the required sample size or to shorten the duration of the trial.
PURPOSE OF REVIEW: The aim of this article is to review the latest clinical trials in neurological diseases where magnetic resonance imaging was used to assess treatment outcome. RECENT FINDINGS: The unique sensitivity of magnetic resonance imaging for detecting disorders in the brain has made it an attractive noninvasive tool for assessing treatment efficacy in several diseases. Volumetric and functional magnetic resonance imaging have proved to represent robust biomarkers for the evaluation of anti-Alzheimer treatments, and have demonstrated a significant impact of cholinesterase inhibitors. The optimization of thrombolytic therapy in acute ischemic stroke has concentrated on the quantification of the ischemic penumbra, using perfusion-weighted and diffusion-weighted imaging. Standard assessment of T2 or fluid-attenuated inversion recovery lesion load remains the method of choice to evaluate new therapeutic strategy in multiple sclerosis. Other nonconventional quantitative magnetic resonance imaging techniques such as magnetic resonance volumetry, magnetization transfer imaging, diffusion-weighted imaging, or magnetic resonance spectroscopy are increasingly used in the field. SUMMARY: Magnetic resonance imaging has become a major surrogate marker of treatment response in clinical trials of neurological disorders, offering the possibility to reduce the required sample size or to shorten the duration of the trial.
Authors: Anna Caroli; Annapaola Prestia; Sara Wade; Kewei Chen; Napatkamon Ayutyanont; Susan M Landau; Cindee M Madison; Cathleen Haense; Karl Herholz; Eric M Reiman; William J Jagust; Giovanni B Frisoni Journal: Alzheimer Dis Assoc Disord Date: 2015 Apr-Jun Impact factor: 2.703
Authors: Dominic Holland; James B Brewer; Donald J Hagler; Christine Fennema-Notestine; Christine Fenema-Notestine; Anders M Dale Journal: Proc Natl Acad Sci U S A Date: 2009-12-08 Impact factor: 11.205
Authors: John Suckling; Anna Barnes; Dominic Job; David Brennan; Katherine Lymer; Paola Dazzan; Tiago Reis Marques; Clare MacKay; Shane McKie; Steve R Williams; Steven C R Williams; Bill Deakin; Stephen Lawrie Journal: Hum Brain Mapp Date: 2011-03-21 Impact factor: 5.038
Authors: Karren Towgood; Gareth J Barker; Alejandro Caceres; William R Crum; Robert D C Elwes; Sergi G Costafreda; Mitul A Mehta; Robin G Morris; Tim J von Oertzen; Mark P Richardson Journal: Hum Brain Mapp Date: 2015-03-02 Impact factor: 5.038